However, the administration of MAPK/Erk1/2 inhibitor has been shown to avert kidney damage, including decreasing HMGB1 secretion from renal epithelial cells and urine accumulation (Zmijewska et al. 2021). This evidence concerns the gene HMGB1 and Nephropathy.